Streamlining Manufacturing Strategies for Complex Allogeneic T-Cell Therapies
- Incorporating complex allogeneic edits as cell line development to reduce additional editing cycles
- Refining scale up readiness to accelerate timelines while protecting product quality and regulatory compliance
- Aligning with regulators on GMP editing component guidelines